Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

NCT00827684 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Irinotecan
DRUG: Temsirolimus

Sponsor

Vejle Hospital